GlassScriptPhysician profile
Richard M Herman
NPI 1114080280
$1,832.36
in general payments reported to CMS, 2019-2025
15 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.90 · 2020: $114 · 2021: $374 · 2022: $160 · 2023: $494 · 2024: $486 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $572.57 | 2021-2025 | Nucala |
| Genzyme Corporation | $520.54 | 2021-2025 | |
| Optinose US, INC. | $341.63 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $145.43 | 2019-2024 | Dupixent |
| Abbvie INC. | $59.54 | 2021 | |
| Smith+Nephew, INC. | $43.05 | 2022-2023 | Collagenase Santyl |
| Alk-Abello, INC | $30.24 | 2019-2021 | |
| Misonix INC | $22.14 | 2020 | |
| Organogenesis INC. | $15.76 | 2021 | |
| Medtronic, INC. | $15.68 | 2021 | |
| Hikma Pharmaceuticals USA | $13.96 | 2023 | Ryaltris |
| Acera Surgical, INC. | $13.63 | 2019 | |
| Merck Sharp & Dohme LLC | $13.46 | 2021 | |
| Intersect Ent, INC. | $13.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.